Pol Jonathan G, Lévesque Sarah, Workenhe Samuel T, Gujar Shashi, Le Boeuf Fabrice, Clements Derek R, Fahrner Jean-Eudes, Fend Laetitia, Bell John C, Mossman Karen L, Fucikova Jitka, Spisek Radek, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo
Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
INSERM, Paris, France.
Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.
溶瘤病毒以免疫原性方式选择性地靶向并杀死癌细胞，从而有助于建立具有治疗意义的肿瘤特异性免疫反应。2015年，美国食品药品监督管理局（FDA）批准溶瘤单纯疱疹病毒T-VEC用于晚期黑色素瘤患者。自那时起，已经开展了大量试验来评估多种溶瘤病毒在患有各种恶性肿瘤的患者中的安全性和有效性。在此，我们总结溶瘤病毒疗法领域最近的临床前和临床进展。
